Wet AMD treatment approved in Europe

March 15, 2007

Toronto-Novadaq Technologies said the European Union has approved the OPTTX System, a minimally invasive treatment for wet age-related macular degeneration.

Toronto-Novadaq Technologies said the European Union has approved the OPTTX System, a minimally invasive treatment for wet age-related macular degeneration.

The company is initiating post-market patient registry studies.

The diagnostic and therapeutic system uses a proprietary imaging technology to identify the disease state, then offers targeted treatment via choroidal vessel closure, which can be done alone or in combination with anti-VEGF therapy.